Insulin delivery automation via continuous subcutaneous infusion (CSII)

"Insulin delivery automation via continuous subcutaneous infusion" refers to the use of an external, programmable medical device—commonly called an **insulin pump**—to deliver rapid‐acting insulin continuously through a small catheter placed under the skin. This approach is designed to more closely replicate normal pancreatic function by providing adjustable basal rates and bolus doses at mealtimes. The system can be further automated with integration of continuous glucose monitoring sensors that allow for real-time adjustments in insulin delivery based on sensor data. This method is widely used in intensive management of type 1 diabetes and select cases of type 2 diabetes where conventional injection regimens do not provide adequate control or flexibility. It is not itself a molecular target but rather a therapeutic technology that acts by delivering exogenous insulin—the actual molecular agent acting on the body’s endogenous **insulin receptor**—to achieve glycemic control.

Other names

Continuous subcutaneous insulin infusionCSIIInsulin pump therapyAutomated insulin delivery systems

Provides continuous subcutaneous administration of insulin via programmable pump to mimic physiological insulin secretion and improve glycemic control